The Medios Group is expanding its product portfolio and entering the medicinal cannabis market. To this end, Medios is partnering with the Dutch company Bedrocan International B.V. ("Bedrocan"), a leading international manufacturer of pharmaceutical-grade cannabis. Medios secures exclusive distribution rights for Bedrocan products in Germany, Spain, Belgium, Italy, and Austria.
The agreement initially covers medicinal cannabis from Bedrocan's EU-GMP -certified Danish facility and will expand to include products from other Bedrocan production sites as of January 1, 2027. The partnership has already been established with a focus on the German market and will be gradually expanded to additional EU countries over the next two years. It builds on Medios extensive footprint in the German and EU pharmacy market and many years of experience in GDP -certified pharmaceutical logistics.
Cannaflos, "Gesellschaft fur medizinisches Cannabis mbH", will support Medios as a distribution partner in Germany. Strategic importance for Medios: Medicinal cannabis is currently used, among other things, to relieve pain, nausea and loss of appetite in patients, for example, in the context of oncological therapies. With the expansion of the product portfolio, Medios is specifically strengthening its expertise in oncology and neurology as well as in other indication areas where supportive treatments are required.
The move underlines Medios' positioning as a comprehensive partner for patient-specific therapies. In Germany, an increasing number of patients are benefiting from access to medicinal cannabis. Medios is specifically targeting the segment of reimbursable medicinal cannabis, ensuring independence from potential legislative changes affecting the self-payer market.
